A5002965160- Cancer Immunotherapy and Biomarkers
- Glioma Diagnosis and Treatment
- CAR-T cell therapy research
- Immunotherapy and Immune Responses
- Melanoma and MAPK Pathways
- Cancer Genomics and Diagnostics
- Cutaneous Melanoma Detection and Management
- Brain Metastases and Treatment
- Lung Cancer Treatments and Mutations
- Lung Cancer Diagnosis and Treatment
- CNS Lymphoma Diagnosis and Treatment
- Lung Cancer Research Studies
- Lymphoma Diagnosis and Treatment
- Cancer Treatment and Pharmacology
- Intraperitoneal and Appendiceal Malignancies
- Immune cells in cancer
- Radiomics and Machine Learning in Medical Imaging
- Breast Cancer Treatment Studies
- Monoclonal and Polyclonal Antibodies Research
- Nanoplatforms for cancer theranostics
- Meningioma and schwannoma management
- Chronic Lymphocytic Leukemia Research
- Cancer, Lipids, and Metabolism
- HER2/EGFR in Cancer Research
- T-cell and B-cell Immunology
Memorial Sloan Kettering Cancer Center
2016-2025
Kettering University
2014-2024
Varian Medical Systems (Switzerland)
2024
AstraZeneca (Finland)
2024
AstraZeneca (Brazil)
2024
Pfizer (United Kingdom)
2024
Astellas Pharma (China)
2024
Bayer (Germany)
2024
Cancer Research And Biostatistics
2006-2023
Statistical Service
2011-2023
Purpose Ipilimumab is a standard treatment for metastatic melanoma, but immune-related adverse events (irAEs) are common and can be severe. We reviewed our large, contemporary experience with ipilimumab outside of clinical trials to determine the frequency use systemic corticosteroid or anti-tumor necrosis factor α (anti-TNFα) therapy effect these therapies on overall survival (OS) time failure (TTF). Patients Methods retrospectively medical records patients melanoma who had received between...
PURPOSE: Several single-institution phase II trials have reported that the Dartmouth regimen (dacarbazine, cisplatin, carmustine, and tamoxifen) can induce major tumor responses in 40% to 50% of stage IV melanoma patients. This study was designed compare overall survival time, rate objective response, toxicity with standard dacarbazine treatment PATIENTS AND METHODS: In this multicenter III trial, 240 patients measurable were randomized receive (dacarbazine 220 mg/m 2 cisplatin 25 days 1 3,...
Abstract BACKGROUND As the U.S. population ages, there is an emerging need to characterize “functional age” of older patients with cancer tailor treatment decisions and stratify outcomes based on factors other than chronologic age. The goals current study were develop a brief, but comprehensive, primarily self‐administered cancer‐specific geriatric assessment measure determine its feasibility as measured by 1) percentage able complete their own, 2) length time complete, 3) patient...
The purpose of this study was to analyze prognostic factors for patients with newly diagnosed primary CNS lymphoma (PCNSL) in order establish a predictive model that could be applied the care and design prospective clinical trials.Three hundred thirty-eight consecutive PCNSL seen at Memorial Sloan-Kettering Cancer Center (MSKCC; New York, NY) between 1983 2003 were analyzed. Standard univariate multivariate analyses performed. In addition, formal cut point analysis used determine most...
PURPOSE: This phase II study evaluated weekly trastuzumab and paclitaxel therapy in women with HER2-normal HER2-overexpressing metastatic breast cancer. Efficacy was correlated immunohistochemical fluorescent situ hybridization (FISH) assay results. PATIENTS AND METHODS: Eligible patients had bidimensionally measurable Up to three prior chemotherapy regimens, including anthracycline taxane therapy, were allowed. Trastuzumab 4 mg/kg 90 mg/m 2 administered on week 1, subsequent weeks. HER2...
Abstract BACKGROUND: Ipilimumab is a monoclonal antibody that antagonizes cytotoxic T lymphocyte antigen‐4, negative regulator of the immune system. The authors report on advanced refractory melanoma patients treated in compassionate use trial ipilimumab at Memorial Sloan‐Kettering Cancer Center. METHODS: Patients with were 10 mg/kg every 3 weeks for 4 doses. Those evidence clinical benefit Week 24 (complete response [CR], partial [PR], or stable disease [SD]) then received 12 weeks....
Uveal melanoma is characterized by mutations in GNAQ and GNA11, resulting mitogen-activated protein kinase pathway activation.To assess the efficacy of selumetinib, a selective, non-adenosine triphosphate competitive inhibitor MEK1 MEK2, uveal melanoma.Randomized, open-label, phase 2 clinical trial comparing selumetinib vs chemotherapy conducted from August 2010 through December 2013 among 120 patients with metastatic at 15 academic oncology centers United States Canada.One hundred one were...
<b>Background:</b> Diagnosis of leptomeningeal metastasis (LM) has become increasingly frequent. The diagnostic gold standard been CSF cytology, but MRI is now used routinely for diagnosis. and prognosis LM not studied in the era. <b>Methods:</b> Patients with from 2002 through 2004 were identified a neurology database, as well by reviewing all abnormal cytologies pathology database. was made malignant cytology or imaging; suspicious cases treated also included. <b>Results:</b> A total 187...
Cancer spread to the central nervous system (CNS) often is diagnosed late and unresponsive therapy. Mechanisms of tumor dissemination evolution within CNS are largely unknown because limited access tissue.We sequenced 341 cancer-associated genes in cell-free DNA from cerebrospinal fluid (CSF) obtained through routine lumbar puncture 53 patients with suspected or known involvement by cancer.We detected high-confidence somatic alterations 63% (20 32) metastases solid tumors, 50% (six 12)...
Bruton tyrosine kinase (BTK) links the B-cell antigen receptor (BCR) and Toll-like receptors with NF-κB. The role of BTK in primary central nervous system (CNS) lymphoma (PCNSL) is unknown. We performed a phase I clinical trial ibrutinib, first-in-class inhibitor, for patients relapsed or refractory CNS lymphoma. Clinical responses to ibrutinib occurred 10 13 (77%) PCNSL, including five complete responses. only PCNSL resistance harbored mutation within coiled-coil domain CARD11, known...
Abstract International cancer registries make real-world genomic and clinical data available, but their joint analysis remains a challenge. AACR Project GENIE, an international registry collecting from 19 centers, makes &gt;130,000 patients publicly available through the cBioPortal for Cancer Genomics (https://genie.cbioportal.org). For 25,000 patients, additional longitudinal data, including treatment outcome are being collected by GENIE Biopharma Collaborative using PRISSMM curation...
Ipilimumab, a monoclonal antibody against cytotoxic T lymphocyte antigen 4 (CTLA-4), has been shown to improve survival in patients with advanced metastatic melanoma. It also enhances immunity NY-ESO-1, cancer/testis expressed subset of To characterize the association between immune response and clinical outcome, we first analyzed NY-ESO-1 serum by ELISA 144 ipilimumab-treated melanoma found 22 140 (16%) seropositive at baseline 31 (22%) following treatment. These NY-ESO-1–seropositive had...
Advanced, metastatic melanomas frequently grow in subcutaneous tissues and portend a poor prognosis. Though are largely composed of adipocytes, the mechanisms by which adipocytes influence melanoma poorly understood. Using vitro vivo models, we find that increase proliferation invasion adjacent cells. Additionally, directly transfer lipids to cells, alters tumor cell metabolism. Adipocyte-derived transferred cells through FATP/SLC27A family lipid transporters expressed on surface. Among six...
Objective A study was undertaken to examine the association between incident cancer and subsequent risk of stroke. Methods Using Surveillance, Epidemiology, End Results–Medicare linked database, we identified patients with a new primary diagnosis breast, colorectal, lung, pancreatic, or prostate from 2001 through 2007. These were individually matched by age, sex, race, registry, medical comorbidities group Medicare enrollees without cancer, each pair followed 2009. Validated codes used...
Abstract Background. Subtypes of melanoma, such as mucosal, uveal, and acral, are believed to result in worse prognoses than nonacral cutaneous melanoma. After a diagnosis distant metastatic disease, however, the overall survival patients with cutaneous, unknown primary melanoma has not been directly compared. Materials Methods. We conducted single-center, retrospective analysis 3,454 diagnosed metastases from 2000 2013, identified prospectively maintained database. examined subtype, date...
To analyze long-term outcomes after treatment discontinuation of anti-programmed death-1 (anti-PD-1) therapy in a cohort patients with melanoma the longest follow-up yet available to our knowledge, including majority treated outside clinical trial. We also assessed efficacy retreatment anti-PD-1 or without ipilimumab relapsing patients.We retrospectively analyzed all nonuveal, unresectable stage III/IV single-agent at Memorial Sloan Kettering from 2009-2018 who had discontinued and least 3...